| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
87,040,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company. Co. is engaged in developing and commercializing targeted therapies for patients with genomically-defined cancers. Co.'s main product candidate, DAY101 (tovorafenib), is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor. Co.'s second product candidate, pimasertib, is an oral, highly-selective small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK), a well-characterized key signaling node in the RAS/mitogen-activated protein kinase pathway.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
2,244,684 |
4,978,018 |
| Total Buy Value |
$0 |
$0 |
$24,978,318 |
$65,978,328 |
| Total People Bought |
0 |
0 |
1 |
3 |
| Total Buy Transactions |
0 |
0 |
4 |
7 |
| Total Shares Sold |
225,453 |
235,538 |
246,104 |
4,525,329 |
| Total Sell Value |
$3,837,225 |
$3,955,119 |
$4,100,690 |
$62,122,635 |
| Total People Sold |
4 |
4 |
4 |
8 |
| Total Sell Transactions |
14 |
18 |
25 |
103 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bender Jeremy |
Chief Executive Officer |
• • – |
2022-07-18 |
4 |
AS |
$20.00 |
$52,003 |
D/D |
(2,600) |
1,258,692 |
|
- |
|
| York Charles N Ii |
COO, CFO and Secretary |
• – – |
2022-07-08 |
4 |
AS |
$20.00 |
$28,320 |
D/D |
(1,416) |
333,865 |
|
- |
|
| Bender Jeremy |
Chief Executive Officer |
• • – |
2022-07-08 |
4 |
AS |
$20.00 |
$35,900 |
D/D |
(1,795) |
1,261,292 |
|
- |
|
| Papanek Julie |
Director |
– • – |
2022-07-08 |
4 |
AS |
$20.00 |
$24,840 |
I/I |
(1,242) |
461,958 |
|
- |
|
| Bender Jeremy |
Chief Executive Officer |
• • – |
2022-07-05 |
4 |
AS |
$20.00 |
$17,140 |
D/D |
(857) |
1,263,087 |
|
- |
|
| York Charles N Ii |
COO, CFO and Secretary |
• – – |
2022-07-05 |
4 |
AS |
$20.00 |
$16,000 |
D/D |
(800) |
335,281 |
|
- |
|
| Papanek Julie |
Director |
– • – |
2022-07-05 |
4 |
AS |
$20.00 |
$16,000 |
I/I |
(800) |
463,200 |
|
- |
|
| Bender Jeremy |
Chief Executive Officer |
• • – |
2022-07-01 |
4 |
AS |
$20.00 |
$34,920 |
D/D |
(1,746) |
1,263,944 |
|
- |
|
| Blackman Samuel C. |
Chief Medical Officer |
• – – |
2022-07-01 |
4 |
AS |
$18.24 |
$187,158 |
D/D |
(10,000) |
1,306,718 |
|
- |
|
| York Charles N Ii |
COO, CFO and Secretary |
• – – |
2022-07-01 |
4 |
AS |
$20.00 |
$29,580 |
D/D |
(1,479) |
336,081 |
|
- |
|
| Atlas Venture Opportunity Fund I, L.p. |
10% Owner |
– – • |
2022-07-01 |
4 |
AS |
$0.00 |
$0 |
D/D |
(198,280) |
793,116 |
|
- |
|
| Papanek Julie |
Director |
– • – |
2022-07-01 |
4 |
AS |
$20.00 |
$20,000 |
I/I |
(1,000) |
464,000 |
|
- |
|
| Gladstone Michael |
Director |
– • – |
2022-06-17 |
4 |
B |
$15.00 |
$11,500,005 |
I/I |
766,667 |
766,667 |
2.1 |
- |
|
| Atlas Venture Associates Opportunity I, Llc |
10% Owner |
– – • |
2022-06-17 |
4 |
B |
$15.00 |
$11,500,005 |
D/D |
766,667 |
766,667 |
2.45 |
- |
|
| Blavatnik Len |
Affiliate of 10% Owner |
– – – |
2022-06-17 |
4 |
B |
$15.00 |
$18,000,000 |
D/D |
1,200,000 |
10,684,638 |
2.44 |
- |
|
| Blackman Samuel C. |
Chief Medical Officer |
• – – |
2022-06-15 |
4 |
AS |
$16.26 |
$813,155 |
D/D |
(50,000) |
1,316,718 |
|
- |
|
| Blavatnik Len |
Affiliate of 10% Owner |
– – – |
2022-01-20 |
4 |
B |
$14.73 |
$67,976 |
D/D |
4,615 |
9,484,638 |
2.44 |
- |
|
| Blavatnik Len |
Affiliate of 10% Owner |
– – – |
2022-01-19 |
4 |
B |
$14.70 |
$864,566 |
D/D |
58,818 |
9,480,023 |
2.44 |
- |
|
| Blavatnik Len |
Affiliate of 10% Owner |
– – – |
2022-01-18 |
4 |
B |
$14.26 |
$619,367 |
D/D |
43,429 |
9,421,205 |
2.44 |
- |
|
| Blackman Samuel C. |
Chief Medical Officer |
• – – |
2022-01-03 |
4 |
AS |
$16.95 |
$171,018 |
D/D |
(10,000) |
1,366,718 |
|
- |
|
| Canaan Partners Xi Llc |
10% Owner |
– – • |
2021-12-21 |
4 |
D |
$0.00 |
$0 |
D/D |
(536,000) |
9,663,645 |
|
- |
|
| Canaan Partners Xi Llc |
10% Owner |
– – • |
2021-12-08 |
4 |
D |
$0.00 |
$0 |
D/D |
(536,000) |
10,199,645 |
|
- |
|
| Takeda Ventures, Inc. |
10% Owner |
– – • |
2021-12-08 |
4 |
S |
$18.03 |
$1,989,394 |
I/I |
(110,338) |
6,120,124 |
|
- |
|
| Takeda Ventures, Inc. |
10% Owner |
– – • |
2021-12-07 |
4 |
S |
$18.43 |
$3,507,475 |
I/I |
(186,935) |
6,230,462 |
|
- |
|
| Takeda Ventures, Inc. |
10% Owner |
– – • |
2021-12-06 |
4 |
S |
$18.05 |
$1,763,341 |
I/I |
(97,692) |
6,417,397 |
|
- |
|
174 Records found
|
|
Page 6 of 7 |
|
|
